Agricultural and Veterinary Chemicals Code (Efficacy Criteria) Determination 2014

The Determination turns on a small set of statutory concepts, each of which alters how the APVMA assesses applications under the Agvet Code.

• "Effective" or "would be effective": The instrument provides criteria the APVMA will accept as establishing that a product use is effective for Code purposes. The Determination is made for subsection 5B(1) of the Agvet Code and therefore operates as the statutory benchmark for effectiveness in that locus (instrument heading and preamble).

• Type‑based categories (s 3 and s 5): For agricultural products (Part 2) the Determination lists product types that, if used as instructed, are "or would be" effective: domestic or home garden products (narrowly defined), adjuvants/wetters/surfactants, drift retardants, plant growth regulators, semiochemical mating disruptors/lures, defoliants, spray‑marker dyes, and mosquito coils or candles (s 3(1)(a)(i)-(viii)). For veterinary products (Part 3) the listed types include counterirritants/rubifacients/poultices, enzymes, direct‑fed microbials or probiotics, pet food containing those ingredients, autogenous vaccines subject to permit (but only if they comply with specified guidelines as in force on commencement), and sheep branding substances (s 5(1)(a)(i)-(v)).

• Active‑constituent continuity requirement (s 3(1)(b); s 5(1)(b)): The type‑based route is conditioned on each active constituent in the proposed product being used in one or more other registered chemical products for an equivalent use (agricultural: "equivalent pest or purpose at equivalent rates of active constituent application"; veterinary: "contain similar amounts of the active constituent and have similar claims and use patterns"). This embeds a reliance on previously registered uses or comparable product formulations.

• Demonstrated‑effectiveness evidence buckets (s 4(b); s 6(b)): The Determination enumerates evidentiary categories the APVMA will accept: results from efficacy trials or experiments; valid scientific argument; demonstrated history of sale and effective use in equivalent uses; full results from overseas trials plus associated overseas regulator assessment reports; and combinations of two or more. For veterinary products the list is expanded to specify types of pharmacological and target animal studies (dose determination/confirmation, pharmacokinetics, pharmacodynamics), clinical case studies, compatibility or palatability studies, plus the other buckets (s 6(b)(i)-(vi)).

• Reference to the Agvet Code substantive effects: The Determination links the "would achieve" standard to one of the effects set out in paragraphs 4(2)(a)-(e) (agricultural) and 5(2)(a)-(d) (veterinary) of the Agvet Code. The Determination does not reproduce those effects; it treats them as incorporated by reference.

• APVMA procedural discretion and guidance (notes to s 4 and s 6): The instrument explicitly states the APVMA will decide, case by case, which of the listed matters are necessary in a particular case, and will also take into account other relevant matters under subsection 5B(2) of the Code. The APVMA’s data and regulatory guidelines made under section 6A of the Code, and published on its website, specify kinds of data considered sufficient.

• Temporal freeze for autogenous vaccines (s 5(1)(a)(iv)): The autogenous vaccine pathway is available only if the product and its use "complies with, or would comply with, the guidelines issued by the APVMA in relation to autogenous vaccines under section 6A of the Agvet Code and as in force on the day this Determination commences." That is a specific reference to the version of the autogenous vaccine guidelines existing on commencement.

These concepts create operational rules that narrow or broaden the evidence required to satisfy the Code’s effectiveness test, allocate discretion to the APVMA about evidentiary sufficiency, and link the Determination directly to the APVMA’s data/regulatory guidance frameworks.

This Determination affects several discrete groups, and it changes the allocation of obligations and decision rights between them.

• Applicants and registrants of agricultural chemical products: Manufacturers or sponsors proposing registration, label changes, or permits for agricultural chemicals will use the Determination to assess what evidence the APVMA will accept as showing a proposed use is effective. Under the type‑based route (s 3), firms proposing products that fall within the listed categories (for example, adjuvants, plant growth regulators, semiochemical lures, mosquito coils) can obtain recognition of effectiveness so long as each active constituent is already used in other registered products for equivalent uses. This benefits sponsors that are producing variants of active constituents already present in the market, by lowering the evidentiary threshold for effectiveness compared with unsupported novel actives.

• Applicants and registrants of veterinary chemical products: Animal‑health product sponsors will be affected similarly. The listed veterinary categories (s 5) include enzymes, probiotics, certain pet foods, autogenous vaccines (subject to specified guidelines), and particular topical agents. The active‑constituent continuity requirement (s 5(1)(b)) means sponsors of new products based on existing active constituents with similar amounts and claims can rely on the type route.

• Small producers and consumer‑facing suppliers: The Determination expressly identifies "domestic or home garden products" for agricultural uses but narrowly limits that term to insecticides, herbicides, fungicides, miticides and nematicides, molluscicides, rodenticides or dog and cat repellents sold via normal retail outlets (s 3(2)(a)). It excludes swimming pool or spa sanitising products (s 3(2)(b)). Retailers and consumer product manufacturers must evaluate whether their products fall within the narrow retail definition in order to benefit from the type‑based route.

• Developers of novel active constituents, or products with novel claims: The Determination makes clear that where the active constituent is not used in other registered products for equivalent uses, sponsors will need to rely on the demonstrated‑effectiveness evidence buckets (s 4; s 6). That typically requires trials, studies or overseas assessment reports. The cost and time to generate such evidence fall on sponsors.

• APVMA and assessors: The Determination formalises the types of evidence APVMA assessors may accept and underscores their discretion to determine on a case‑by‑case basis which matters are necessary (notes to s 4 and s 6). APVMA will therefore make consequential administrative decisions about sufficiency of particular trials, overseas reports, or valid scientific argument.

• Veterinary permit applicants for autogenous vaccines: The autogenous vaccine pathway is conditional on compliance with the APVMA’s autogenous vaccine guidelines "as in force on the day this Determination commences" (s 5(1)(a)(iv)). Producers seeking permits for autogenous vaccines must therefore pay attention to the guideline version specified.

• Downstream users and consumers: Because the Determination potentially lowers the evidentiary threshold for products that are variants of already‑registered active constituents, consumers may see faster market entry of reformulated products in the enumerated categories. Conversely, novel actives will require more substantial evidentiary support, potentially delaying their availability.

• Retail channels and distribution: The restriction that domestic/home garden products be those available to the general public via "normal retail outlets" (s 3(2)(a)) affects distribution. Products sold only through farm‑supply specialty channels may not be captured by that retail safety valve and will be assessed under the normal demonstrated‑effectiveness route.

Who pays: The Determination places the practical cost of generating or assembling acceptable evidence on applicants and registrants. APVMA’s role is to evaluate that material under its case‑by‑case discretion, guided by data and regulatory guidelines. The Determination does not create or levy fees itself; it changes the evidentiary regime that determines what applicants must fund.

The Determination creates duties on applicants and confers procedural positions in the APVMA assessment process. The instrument does not create criminal offences or penalty regimes itself; it operates as a definitional tool for effectiveness in the administrative framework of the Agvet Code.

Duties on applicants and registrants

• Establishing effectiveness: For a proposed use to be treated as "effective" under subsection 5B(1) of the Agvet Code, applicants must either fit within the type‑based criteria (Part 2 s 3 for agricultural; Part 3 s 5 for veterinary) or assemble evidence of demonstrated effectiveness per s 4 (agricultural) or s 6 (veterinary). The Determination specifies the categories of evidence that will be accepted, and applicants therefore have the duty to supply one or more of those types (s 4(b)(i)-(v); s 6(b)(i)-(vi)) as appropriate.

• Active‑constituent continuity: Where relying on a type‑based category, each active constituent in the product must be shown to be used in one or more other registered products for an equivalent use (s 3(1)(b)) or used in one or more other registered veterinary products containing similar amounts and having similar claims and use patterns (s 5(1)(b)). Sponsors bear the duty to demonstrate that continuity.

• Compliance with autogenous vaccine guidelines: Applicants seeking to rely on s 5(1)(a)(iv) must show compliance with the APVMA’s autogenous vaccine guidelines as in force on commencement (s 5(1)(a)(iv)). This is a binary compliance duty tied to a specific version of the guideline.

APVMA rights and procedural duties

• Case‑by‑case discretion: The APVMA retains the right and duty to decide which of the listed matters are necessary in a particular case. The Determination expressly states the APVMA will consider, on a case by case basis, which of the matters (trials, scientific argument, history of sale, overseas data) are necessary to demonstrate effectiveness (notes to s 4 and s 6). That gives APVMA procedural discretion in deciding sufficiency.

• Consideration of other relevant matters: The APVMA will also take into account other relevant matters under subsection 5B(2) of the Code (notes to s 4 and s 6). The Determination does not list those matters; it references the Code for additional factors.

• Use of APVMA data and regulatory guidelines: The Determination defers to the APVMA’s data guidelines and regulatory guidelines made under section 6A of the Agvet Code, which are published on the APVMA website, for specifics about the kinds of data considered sufficient. The APVMA therefore has the right to make and update these guidelines and to use them in assessments.

Rights for applicants

• Reliance on enumerated evidence: Applicants have the procedural right to present any of the listed forms of evidence (efficacy trials, valid scientific argument, history of effective use, overseas trial results with regulator assessments, or combinations) to establish effectiveness (s 4(b); s 6(b)).

• Type‑based presumption of effectiveness: If a product falls within a listed product type and satisfies the active‑constituent continuity condition, the Determination treats the use as, or would be, effective (s 3(1); s 5(1)). That creates a predictable route to be treated as effective for certain product categories.

Limitations and procedural boundaries

• The Determination sets no absolute list of necessary studies; instead it provides a menu of evidentiary options and leaves assessment of necessity to APVMA (notes to s 4 and s 6). That produces uncertainty about which specific studies will be required in a particular case.

• The autogenous vaccine pathway is time‑locked to the guidelines in force on commencement, so applicants cannot rely on later guideline changes for that specific provision (s 5(1)(a)(iv)).

• The Determination does not create a freestanding approval right; it defines when a use is to be treated as effective for the purposes of the Agvet Code. Final registration, labelling and other regulatory steps remain subject to the Code and APVMA assessment processes.

In short, the Determination imposes data and demonstration duties on sponsors and grants them the right to run specified forms of evidence before APVMA, while vesting the APVMA with discretion to determine which material is necessary and sufficient in individual cases.

The Determination itself does not create offences, penalties or a bespoke enforcement regime. It is a statutory interpretative and evidentiary instrument that operates within the enforcement framework of the Agvet Code. The essential enforcement mechanics to note from the Determination text are administrative rather than criminal.

Administrative enforcement role

• APVMA decision‑making: The Determination informs APVMA’s assessments under subsection 5B(1) of the Agvet Code by specifying when a proposed use is to be treated as effective. Enforcement in practice therefore consists of APVMA accepting or rejecting the sufficiency of the evidence presented by an applicant, and proceeding with registration, permits, variations, or refusals under the Agvet Code. The Determination assigns the APVMA discretion to judge necessity and sufficiency of evidence (notes to s 4 and s 6), and enforcement will flow through APVMA administrative processes.

• Reliance on guidelines: The Determination repeatedly links sufficiency to APVMA data and regulatory guidelines made under section 6A of the Code and published on the APVMA website (notes to s 4 and s 6). Compliance with those guidelines will be material to enforcement outcomes. APVMA’s enforcement actions (registration refusal, conditions, or requirements for further data) will reflect whether submissions conform to guideline expectations.

Penalties and legal consequences under the Code

• No new penalties in the Determination text: The Determination does not prescribe penalties or enforcement mechanisms; it operates by clarifying the standard for "effective" use under the Agvet Code. Any penalty or sanction for non‑compliance with registration requirements, misleading claims, or unlawful supply remains governed by the Agvet Code and associated regulations, not by this Determination itself.

Practical enforcement implications

• Administrative requirement to supply evidence: Applicants who fail to supply evidence the APVMA deems necessary may have their applications refused or asked to provide further data. The Determination’s case‑by‑case discretion increases the risk of requests for additional studies or reports, which are administrative burdens rather than criminal penalties.

• Temporal binding for autogenous vaccine compliance: For autogenous vaccines to be taken as effective under s 5(1)(a)(iv), compliance must be with the guideline version in force on the day the Determination commences (s 5(1)(a)(iv)). Non‑compliance with that specific guideline version would therefore impede reliance on the type‑based route for autogenous vaccines.

• Use of overseas regulator assessments: The Determination expressly allows full overseas trial results and associated assessment reports by an overseas regulator to be relied upon (s 4(b)(iv); s 6(b)(iv)). APVMA may accept those reports in lieu of domestic trials, but acceptance is discretionary.

Because enforcement is embedded in the APVMA’s application and registration processes, the practical consequence of non‑compliance is administrative: refusal, requests for further data, or conditional approvals. The Determination does not itself prescribe civil or criminal sanctions.

This Determination is a subordinate instrument made under the Agvet Code and therefore interacts directly with that Act and with the APVMA’s regulatory framework established under the Code.

Statutory linkage and incorporation

• Made for subsection 5B(1) of the Agvet Code: The preamble states the Determination is made for subsection 5B(1) of the Agvet Code. That subsection is the statutory hook the Determination interprets or implements. The instrument therefore alters the meaning or application of provisions relating to the APVMA’s assessment of "effectiveness" under the Code.

• Cross references to Agvet Code paragraphs: The Determination incorporates by reference the substantive effects listed in paragraphs 4(2)(a)-(e) (agricultural) and 5(2)(a)-(d) (veterinary) of the Agvet Code. The Determination does not reproduce those paragraphs; it uses them as the ends that evidence must show will be achieved "to a reasonable degree." This means the Determination’s evidentiary requirements must be read together with the Code’s substantive criteria.

Interaction with APVMA guidelines under s 6A of the Code

• Data and regulatory guidelines: The Determination explicitly states that the APVMA’s data guidelines and regulatory guidelines made under section 6A of the Code and published on the APVMA website "set out information about the kind of data considered sufficient to demonstrate effectiveness in particular cases" (notes to s 4 and s 6). The Determination therefore defers detailed evidentiary standards to the APVMA’s guideline instruments made under s 6A, and these guidelines will be integral to how the Determination operates in practice.

• Autogenous vaccine guideline temporal lock: The autogenous vaccine pathway in s 5(1)(a)(iv) requires compliance with the autogenous vaccine guidelines "as in force on the day this Determination commences." That creates an explicit interaction with the versioning and temporal application of APVMA’s s 6A guidelines.

Commencement and regulatory amendment interplay

• Commencement tied to Amendment Regulation 2013 Measures No. 2: The Determination commences on the commencement of the Agricultural and Veterinary Chemicals Legislation Amendment (2013 Measures No. 2) Regulation 2013. That links the Determination’s operative date to a separate amending regulation, creating a dependency in commencement sequencing.

Administrative law and reviewability

• Administrative decisions affected: Because the Determination shapes the evidentiary standard the APVMA uses to determine effectiveness, it will influence administrative decisions under the Agvet Code (registrations, permits, conditions). Those decisions remain subject to the usual administrative law frameworks (judicial review, merits review where available) established by primary legislation and general administrative law principles; the Determination itself is an instrument the courts would interpret as part of the statutory scheme.

Scope vis‑à‑vis other Commonwealth, State or Territory laws

• No explicit interaction in the text with non‑Code laws: The Determination is narrowly focused on the Agvet Code’s concept of effectiveness and does not refer to other Commonwealth or State statutory regimes (such as environmental protection, workplace safety, consumer law). However, products approved under the Code will still be subject to any other applicable legal requirements outside the Determination.

In sum, the Determination modifies how the Agvet Code’s effectiveness test is operationalised by supplying type‑based and evidence‑based routes and by delegating detail to APVMA guidelines made under s 6A. Assessment outcomes will therefore depend on interplay between this Determination, the Agvet Code paragraphs it references, and APVMA guidelines.

The Determination’s published text gives a minimal amendment history within the instrument itself.

• Date and maker: The instrument is signed and dated by the CEO of the APVMA, Kareena Arthy, on the 25th day of June 2014. The preamble records that the Determination is made for subsection 5B(1) of the Agvet Code.

• Commencement link: The Determination states it "commences on the commencement of the Agricultural and Veterinary Chemicals Legislation Amendment (2013 Measures No. 2) Regulation 2013." This links the operative date to an amendment regulation rather than a standalone commencement date in the Determination.

• Placeholders: The published text contains lines reading "Placeholder 1 of 11" through "Placeholder 11 of 11" immediately following the signature block. These placeholders indicate non‑substantive editorial or publishing placeholders in the available text; the Determination otherwise contains the operative provisions in Parts 1-3.

• No subsequent amendments recorded in the instrument: The Determination text provided does not show any legislative amendments, replacements, or repeal notes subsequent to the 2014 date. The instrument does not record prior versions or changes; it is presented as a single 2014 instrument.

• Interaction with guideline versions: The autogenous vaccine provision (s 5(1)(a)(iv)) references the APVMA’s autogenous vaccine guidelines "as in force on the day this Determination commences." That phrase embeds a temporal reference to a particular version of guideline material as of commencement and thus fixes that aspect of the Determination to a particular point in the guideline history.

• Relation to the underlying Code amendments: Because the Determination commences on the commencement of the 2013 Measures No. 2 Regulation, its operational history is linked to that regulation’s commencement timeline. The Determination itself does not record any later amending instruments.

If researchers require a complete statutory history, including whether this Determination has subsequently been amended, superseded, or revoked, they will need to consult the official Federal Register of Legislation or APVMA records for updates post‑2014. The instrument as provided contains no internal amendment annotations.

The Determination text supplied contains no references to litigation, court decisions, or administrative appeals. It does not cite cases or report any judicial or tribunal treatment of the instrument. The Determination is an administrative legislative instrument that defines evidentiary criteria for APVMA assessment; any litigation would typically involve APVMA decisions that applied the Determination rather than the Determination itself.

What the instrument records

• No cases named: The text does not name judicial decisions, review outcomes, or challenges to the Determination.

• Administrative nature: Because the Determination sets evidentiary thresholds and confers discretion on APVMA assessors to decide on a case‑by‑case basis which matters are necessary (notes to s 4 and s 6), disputes about its application would likely arise in the context of administrative decisions under the Agvet Code (for example, registration refusals, requests for further information, or conditions attached to approvals).

Likely loci of dispute (based on the Determination’s mechanics)

• Sufficiency of evidence: Disputes are most likely to concern whether particular evidence (efficacy trials, overseas assessment reports, "valid scientific argument", demonstrated history of sale) meets the APVMA’s case‑specific expectations under the Determination and associated s 6A guidelines. Those are the kinds of reviewable administrative decisions that could give rise to merits or judicial review proceedings under the Code or general administrative law principles.

• Active‑constituent continuity: Challenges could arise over whether an active constituent in a proposed product is sufficiently similar to that used in other registered products for equivalent uses, or whether amounts and use patterns are similar enough to qualify under s 3(1)(b) or s 5(1)(b).

• Temporal application of guidelines: Litigation could question the effect of the phrase "as in force on the day this Determination commences" for autogenous vaccines (s 5(1)(a)(iv)), for example whether later guideline variations should apply, but the Determination text itself fixes the relevant guideline version.

Absence of recorded litigation in the instrument

• Because the Determination as provided gives no litigation history, researchers should not assume the absence of any challenges; rather, the instrument does not document adjudicative treatment. To determine whether this Determination has been the subject of litigation, one must consult court and tribunal databases and APVMA administrative records beyond the Determination text itself.

In short, the instrument contains no litigation history in its text. Any judicial or tribunal engagement would arise from APVMA decisions applying these criteria and must be researched from external adjudicative records.

The Determination contains several concrete provisions and drafting choices that create traps for the unwary applicant or assessor. These are matters of interpretation or implementation set out in the instrument.

Narrow definition of "domestic or home garden product" (s 3(2))

• The Determination treats "domestic or home garden products" as a distinct type, but narrows that term to products developed only for domestic or home garden purposes and available to the general public via normal retail outlets, and then limits the permitted product types to insecticides, herbicides, fungicides, miticides and nematicides, molluscicides, rodenticides or dog and cat repellents (s 3(2)(a)). This excludes many consumer products and excludes pool/spa sanitising products explicitly (s 3(2)(b)). Applicants who assume a broad retail safety valve may be disappointed if their product falls outside those enumerated categories.

Active‑constituent continuity requirement (s 3(1)(b); s 5(1)(b))

• The type‑based routes require that "each active constituent of the product is used in 1 or more other registered chemical products" for equivalent uses (agricultural) or "contain similar amounts of the active constituent and have similar claims and use patterns" (veterinary). This is an objective requirement applicants must show. For novel active substances, new formulations, or distinct claim packages, this pathway will not be available, necessitating the more detailed evidence streams in s 4/s 6.

"Reasonable degree" standard and case‑by‑case discretion (s 4(a); s 6(a); notes)

• The Determination accepts as sufficient evidence that the use "would, to a reasonable degree, achieve" statutory effects in the Code. That phrase is inherently qualitative and the instrument gives the APVMA discretion to decide which matters are necessary in any case (notes to s 4 and s 6). Applicants face uncertainty about what constitutes a "reasonable degree" in the APVMA’s view unless they conform closely to the APVMA’s published data guidelines under s 6A.

Reliance on overseas trials and associated overseas regulator assessment reports (s 4(b)(iv); s 6(b)(iv))

• The Determination allows full results from overseas efficacy trials and the associated overseas regulator assessment reports to be used. However, the APVMA retains discretion to accept or reject those materials on a case‑by‑case basis. Applicants cannot assume automatic equivalence of overseas regulatory conclusions.

"Valid scientific argument" as an evidence bucket (s 4(b)(ii); s 6(b)(v))

• The Determination lists "valid scientific argument" as a permissible form of evidence. The instrument does not define the term, and the APVMA will decide on a case‑by‑case basis what constitutes a valid argument. Relying solely on argument rather than empirical trial data risks an APVMA finding that more concrete evidence is necessary.

Autogenous vaccines and guideline timing (s 5(1)(a)(iv))

• The autogenous vaccines provision requires the product and its use to comply with the APVMA autogenous vaccine guidelines "as in force on the day this Determination commences." That freezes the operative guideline version for the purposes of the Determination, which may be an important drafting trap for applicants who assume later guideline amendments apply.

No penalties or enforcement detail in the Determination

• Because the instrument does not specify enforcement mechanisms, practitioners must not look to the Determination for sanctions or appeal processes. Enforcement consequences derive from the Agvet Code and administrative procedures; relying on the Determination alone for enforcement expectations is insufficient.

Placeholders and published text integrity

• The presence of "Placeholder 1 of 11" through "Placeholder 11 of 11" in the published text suggests editorial placeholders or formatting gaps in the public file. Practitioners should confirm they are consulting an authoritative version and, where necessary, check the Federal Register of Legislation or APVMA for any corrected or consolidated instrument.

Reliance on APVMA guidelines under section 6A

• The Determination explicitly defers to data and regulatory guidelines made under section 6A of the Code and published on the APVMA website. Those guidelines determine what the APVMA considers sufficient evidence "in particular cases." Therefore, compliance planning must incorporate the current version of these guidelines and not rely solely on the Determination’s text.

In short, the principal gotchas are the narrow product‑type definitions, the need to demonstrate active‑constituent continuity for the type‑based route, the APVMA’s case‑by‑case discretion and qualitative standards, the temporal lock on autogenous vaccine guidelines, and the dependence on external APVMA guidelines. Each of these can materially change the application pathway and evidence burden.

Compliance under this Determination requires a disciplined assessment of which statutory route applies to a proposed product and then assembling the corresponding evidence or demonstrations. The Determination offers two broad compliance pathways: type‑based and evidence‑based. Below are practical, source‑grounded steps, mapped to the Determination’s provisions.

1. Identify the correct pathway

• Type‑based eligibility: Check whether the proposed product is of a listed type. For agricultural products, consult s 3(1)(a)(i)-(viii). For veterinary products, consult s 5(1)(a)(i)-(v). If the product is a "domestic or home garden product", ensure it falls within the narrow statutory definition: developed only for domestic or home garden purposes, available to the general public via normal retail outlets, and is one of the enumerated classes (s 3(2)(a)-(b)).

• Evidence‑based route: If the product is not a listed type or cannot meet the active constituent continuity condition, move to the demonstrated‑effectiveness route in s 4 (agricultural) or s 6 (veterinary).

2. For type‑based compliance, demonstrate active‑constituent continuity

• Agriculture: Show that each active constituent is used in one or more other registered chemical products for an equivalent use , that is, for an equivalent pest or purpose at equivalent rates of active constituent application (s 3(1)(b)). Collect registration numbers, labels, or other APVMA registration documentation for those comparator products to demonstrate equivalence.

• Veterinary: Demonstrate that other registered veterinary products contain similar amounts of the active constituent and have similar claims and use patterns (s 5(1)(b)). Provide label claims, formulation details and comparative use patterns.

3. For demonstrated‑effectiveness compliance, assemble acceptable evidence

• Match evidence types in the Determination: The APVMA will accept one or a combination of the listed materials:

  • Results from efficacy trials or experiments (s 4(b)(i); s 6(b)(i)): For agricultural products, relevant field or laboratory efficacy trials. For veterinary products, target animal efficacy studies, dose determination and confirmation studies, or confirmatory clinical/field studies (s 6(b)(i)).

  • Pharmacological studies for veterinary products (s 6(b)(ii)): Where relevant, provide in vivo or in vitro bioequivalence, pharmacokinetic or pharmacodynamic studies.

  • Other relevant studies (s 6(b)(iii)): For veterinary products, clinical case studies, compatibility or palatability studies may be relevant.

  • Valid scientific argument (s 4(b)(ii); s 6(b)(v)): Where empirical data are limited, prepare a robust scientific rationale supported by authoritative literature and mechanistic data. Be prepared for the APVMA to require supplemental empirical data.

  • Demonstrated history of sale and effective use in equivalent uses (s 4(b)(iii)): Provide market history, export/import data, sales figures, and documented evidence of effective use in comparable jurisdictions.

  • Full results from overseas trials and associated overseas regulator assessment reports (s 4(b)(iv); s 6(b)(iv)): Where relying on overseas data, include full trial datasets and the overseas regulator’s assessment report(s).

• Combine evidence pragmatically: The Determination permits combinations of two or more evidence types (s 4(b)(v); s 6(b)(vi)). A combined dossier (e.g., limited domestic trials plus overseas assessments plus mechanistic argument) may be more persuasive.

4. Consult APVMA data and regulatory guidelines

• The Determination explicitly refers to the APVMA’s data guidelines and regulatory guidelines made under section 6A of the Agvet Code and published on the APVMA website (notes to s 4 and s 6). Those documents provide the detail on study design, reporting standards, and data quality expectations. Tailor trials, reports and dossiers to those guidelines to reduce risk of requests for additional data.

5. Mind the autogenous vaccine timing rule

• If the product is an autogenous vaccine and you seek to rely on s 5(1)(a)(iv), demonstrate compliance with the APVMA autogenous vaccine guidelines "as in force on the day this Determination commences." Identify the guideline version contemporaneous with commencement and show conformity to that version.

6. Prepare to document equivalence claims

• For active‑constituent continuity or similarity of amounts/use patterns, prepare labels, specifications, certificates of analysis, and pharmacological comparisons. The Determination’s wording requires objective demonstration that the active constituents are used in comparable contexts.

7. Expect case‑by‑case discretion and plan contingencies

• Because the APVMA will decide which matters are necessary on a case‑by‑case basis (notes to s 4 and s 6), build contingency plans for additional studies. Budget and timeline planning should account for possible requests by APVMA for further data, trials, or clarifications.

8. Use overseas regulator reports strategically

• Where overseas efficacy trials and regulator assessment reports are relied upon, submit full datasets and the overseas regulator’s assessment. APVMA will consider these materials but retains discretion to require domestic confirmation or additional data.

9. Recordkeeping and compliance documentation

• Maintain comprehensive documentation of trials, manufacturing specifications, labels, comparator product evidence, and distribution channels (to support retail availability claims where relevant). The Determination ties eligibility to verifiable facts (for instance, "available to the general public via normal retail outlets" for domestic products).

10. Seek pre‑submission engagement with APVMA

• Given the Determination’s case‑by‑case discretion, organisers should consider early engagement with APVMA to clarify what evidence will be considered sufficient in that particular instance, and to align trial designs with APVMA expectations as set out in the section 6A guidelines.

These steps follow directly from the Determination’s two pathways and the evidence categories it specifies (s 3-6). Compliance is predominantly about matching the product and its active constituents to the Determination’s categories and assembling the documentary and trial evidence that APVMA accepts in practice under its guidelines.